|
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigation |
1 Section of Nuclear Medicine, Ospedale Maggiore, Trieste, Italy; 2 Department of Internal Medicine, University of Rome "Tor Vergata," Rome, Italy; and 3 Department of Biopathology and Diagnostic Imaging, University of Rome "Tor Vergata," Rome, Italy
Correspondence: For correspondence or reprints contact: Orazio Schillaci, viale Mazzini 121, 00195 Rome, Italy. E-mail:orazio.schillaci{at}uniroma2.it
Our aim was to evaluate the role of SPECT/CT for the diagnosis of diabetic foot infection by labeled leukocytes. Methods: Seventeen patients with 19 clinically suspected sites of infection were included. After leukocyte labeling and administration, planar scans were acquired at 30 min, 4 h, and 24 h for 18 consecutive patients. SPECT/CT was obtained at 6 h. The final diagnosis was established by clinical follow-up (24 mo) in all cases and by bone biopsy for 14 sites. Results: Leukocyte scanning was positive in 16 of 19 lesions and negative in 3. SPECT/CT changed the interpretation of the planar and SPECT images for 10 of 19 suspected sites (52.6%): it excluded osteomyelitis in 6 cases, revealed bone infection in 1 case, and revealed both bone and soft-tissue infection in 3 cases. The hybrid device did not significantly contribute to the evaluation of patients with negative scan results. Conclusion: SPECT/CT can be useful for a more accurate diagnosis of diabetic foot infection by labeled leukocyte imaging.
Key Words: diabetic foot infection hybrid SPECT/CT leukocytes
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |